Recently, RuiZhou Biotech announced the successful completion of a Series B financing round, raising RMB 200 million. The round was led by a prominent investment firm, with continued participation from several existing shareholders. The proceeds will primarily support the advancement of its core vaccine candidates through clinical trials, expansion of manufacturing capacity, and strengthening of its R&D pipeline. RuiZhou Biotech is a biotechnology company focused on developing innovative vaccines to address major infectious diseases and public health challenges. The company currently has multiple vaccine candidates at various stages of development, with its pneumococcal and respiratory syncytial virus (RSV) vaccines already in late-stage clinical trials, demonstrating favorable safety and immunogenicity profiles. The successful Series B financing underscores strong investor confidence in RuiZhou’s technology platform and R&D capabilities, providing crucial financial backing to accelerate its path toward commercialization. Looking ahead, RuiZhou plans to expand international collaborations and bring its high-end, domestically developed vaccines to global markets, contributing to worldwide public health efforts.
近日，瑞宙生物宣布完成2亿元人民币的B轮融资，本轮融资由知名投资机构领投，多家老股东持续跟投。此次融资将主要用于推进其核心疫苗产品的临床试验、扩大生产规模以及加强研发管线布局。瑞宙生物是一家专注于创新型疫苗研发的生物科技公司，致力于应对重大传染病和公共卫生挑战。公司目前拥有多个处于不同研发阶段的疫苗候选产品，其中针对肺炎球菌和呼吸道合胞病毒（RSV）的疫苗已进入临床后期阶段，展现出良好的安全性和免疫原性数据。此次B轮融资的成功，不仅体现了资本市场对瑞宙生物技术平台和研发能力的高度认可，也为其加速产品商业化进程提供了坚实的资金保障。未来，瑞宙生物计划进一步拓展国际合作，推动国产高端疫苗走向全球市场，为全球公共卫生事业贡献力量。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/11258.html